**Name of Journal: *World Journal of Gastroenterology***

**ESPS Manuscript NO: 26492**

**Manuscript Type: TOPIC HIGHLIGHT**

**2016 Liver Transplantation: Global view**

**Metabolic complications in liver transplant recipients**

Jiménez-Pérez M *et al*. Metabolic complications and liver transplantation

**Miguel Jiménez-Pérez,Rocío González-Grande, Edith Omonte Guzman, Víctor Amo Trillo, Juan Miguel Rodrigo López**

**Miguel Jiménez-Pérez,Rocío González-Grande, Edith Omonte Guzman, Víctor Amo Trillo, Juan Miguel Rodrigo López,** Liver transplantation and hepatology unit, UGC de Aparato Digestivo Hospital Regional Universitario, 29010 Málaga, Spain

**Author contributions:** Jiménez-Pérez M, González-Grande R, Omonte Guzmán E, Amo Trillo V and Rodrigo López JM contributed equally to this work.

**Conflict-of-interest statement:** The authors have no conflict of interest to report.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Miguel Jiménez-Pérez,** **MD,** UGC de Aparato Digestivo, Unidad de Hepatología-Trasplante Hepático, Hospital Universitario Regional de Málaga, Avenida Carlos Haya, 29010 Malaga, Spain. [mjimenezp@commalaga.com](mailto:mjimenezp@commalaga.com)

**Telephone:** +34-61095935

**Fax:** +34-951291941

**Received:** April 12, 2016

**Peer-review started:** April 14, 2016

**First decision:** May 12, 2016

**Revised:** May 25, 2016

**Accepted:** June 13, 2016

**Article in press:**

**Published online:**

**Abstract**

The metabolic syndrome (MS), which includes obesity, dyslipidaemia, hypertension and hyperglycaemia according to the most widely accepted definitions now used,is one of the most common post-transplant complications, with a prevalence of 44%-58%. The MS, together with the immunosuppression, is considered the main risk factor for the development of cardiovascular disease (CVD) in transplant recipients, which in turn accounts for 19%-42% of all deaths unrelated to the graft. The presence of MS represents a relative risk for the development of CVD and death of 1.78. On the other hand, non-alcoholic fatty liver disease (NAFLD), considered as the manifestation of the MS in the liver, is now the second leading reason for liver transplantation in the United States after hepatitis C and alcohol. NAFLD has a high rate of recurrence in the liver graft and a direct relation with the worsening of other metabolic disorders, such as insulin resistance or diabetes mellitus. Consequently, it is vitally important to identify and treat as soon as possible such modifiable factors as hypertension, overweight, hyperlipidaemia or diabetes in transplanted patients to thus minimise the impact on patient survival. Additionally, steroid-free regimens are favoured, with minimal immunosuppression to limit the possible effects on the development of the MS.

**Key words:** metabolic syndrome; liver transplantation; risk factors; non-alcoholic fatty liver disease; immunosuppressions

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The metabolic syndrome is a very frequent complication after liver transplantation; indeed, over half transplant patients will eventually develop it. It is also a risk factor for the development of cardiovascular disease, one of the main causes of long-term death after transplantation. The identification and early treatment of such factors as hypertension, dyslipidaemia, obesity and diabetes is crucial to achieve a positive impact on long-term survival of liver transplant patients.

Jiménez-Pérez M,González-Grande R, Omonte Guzmán E, Amo Trillo V, Rodrigo López JM. Metabolic complications in liver transplant recipients. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

The optimization over recent years of the surgical technique and immunosuppressive therapy has led to excellent survival rates after liver transplantation, reaching 90% at one year and 80% at five years[1-3]. This greater survival has, however, been accompanied by an increase in medical complications derived from the transplant, such as the development of de novo malignancies, recurrence of the underlying disease, metabolic complications and cardiovascular diseases, which today constitute the main causes of death unrelated to the graft[4-6]. The metabolic syndrome (MS), which includes obesity, dyslipidaemia, hypertension and hyperglycaemia according to the most widely accepted definitions now used (Table 1)[7,8], is one of the most common post-transplant complications, with a prevalence ranging from 44%-58% in different studies[9-13]. The MS, together with the immunosuppression, is considered the main risk factor for the development of cardiovascular disease (CVD) in transplant recipients, which in turn accounts for 19%-42% of all deaths unrelated to the graft[10,14]. The presence of the MS represents a relative risk for the development of CVD and death of 1.78[15]. On the other hand, non-alcoholic fatty liver disease (NAFLD), considered as the manifestation of the MS in the liver, is now the second leading reason for liver transplantation in the US after hepatitis C and alcohol[16,17]. NAFLD has a high rate of recurrence in the liver graft and a direct relation with the worsening of other metabolic disorders, such as insulin resistance or diabetes mellitus[18]. Consequently, it is vitally important to identify and treat as soon as possible such modifiable factors as hypertension, overweight, hyperlipidaemia or diabetes in transplanted patients to thus minimise the impact on patient survival. Additionally, steroid-free regimens are preferred, with minimal immunosuppression to limit the possible effects on the development of the MS.

**COMPONENTS OF POST-LIVER TRANSPLANT METABOLIC SYNDROME**

***Obesity***

According to the World Health Organisation obesity is determined from the body mass index (BMI) as: overweight BMI: 25-29.9 kg/m2, class I: 30-34.9 kg/m2, class II: 35-39.9 kg/m2 and class III: > 40 kg/m2. Central obesity seems to confer more risk of developing the MS and CVD than peripheral obesity[19,20].

Two considerations concerning obesity and its impact on the results of liver transplantation should be considered; the presence of obesity at the time of transplantation and the development of obesity after transplantation.

Patients who are overweight or obese before the transplant remain overweight or obese after the transplant[9]. Over 15% of patients who are of normal weight when they receive their liver transplant become obese within one year and over 25% within 3 years[9,21]. This can be explained by the correction of the catabolic state induced by the cirrhosis and which disappears after transplantation, as well as the increased appetite due to the absence of chronic disease and the use of drugs like steroids. Weight gain after a transplant is associated with an increased risk for the MS and its complications, such as CVD, kidney disease or NAFLD/non-alcoholic steatohepatitis (NASH) on the liver graft[22,23].

Another point is whether the presence of overweight at the time of transplantation impacts on the short- and long-term results post-transplant. One study found that at 5 years post-transplant there was greater mortality among patients who had a BMI > 35 (class I) and BMI > 40 (class II) when they received their transplant as compared with non-obese patients, though this study did not consider the possible influence of the presence of ascites[24].This may, therefore, be a confounding factor, as it could have been the presence of ascites at the time of transplantation that was associated with greater post-transplant mortality and not the greater BMI of the patients. Other studies, however, that considered obesity but corrected for ascites found no differences in survival between obese and non-obese patients, probably due to the more exhaustive control of cardiovascular risk factors undergone by obese patients during the pre-transplant period. This, therefore, highlights the need to consider the presence of ascites at the time of transplantation and its association with worse results when interpreting the impact of the BMI on post-transplant results[25]. Even in cases of morbid obesity excellent survival rates can be achieved, both for the graft and the patient, provided there is adequate selection[25,26]. A study by the United Network of Organ Sharing found a lower survival rate among patients with a BMI > 40 and a high MELD score[27]. Nevertheless, adoption of vigorous measures to prevent and correct overweight must be taken from before the time of transplant.

***Hypertension***

Although the incidence of hypertension before transplantation is low it can still reach 40%-85% afterwards[28-30]. The immunosuppressive drugs, either alone or combined with other factors, are the main cause of the onset of hypertension, due mainly to the renal and systemic haemodynamic changes they induce. Steroids can also induce hypertension due to their mineralocorticoid effect as well as the increase in vascular resistance and cardiac contractility. Calcineurin inhibitors, mainly cyclosporine rather than tacrolimus[31,32], produce hypertension due to vasoconstriction of the afferent renal arteriole, which in turn induces reabsorption of sodium and water and volume expansion, with the resulting increase in blood pressure[33]. mammalian target of rapamycin (mTOR) inhibitors, when combined with calcineurin inhibitors, can also cause hypertension[34].

Salt-restriction diets and the correction of other associated risk factors accompanied by physical activity are determinant for the prevention and control of hypertension. If drugs are required to control the hypertension, calcium antagonists are considered the first choice as they act directly on the pathophysiological mechanism producing hypertension. In liver transplant patients the recommended drugs are amlodipine/felodipine because they do not interfere with the hepatic metabolism of calcineurin, unlike diltiazem, verapamil or nifedipine, which interfere with the cytochrome P450 and can increase the levels of calcineurin inhibitors and thus their possible toxicity. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers have a limited effect when used as single therapy during the early post-transplant period because the activity of the plasma renin system is low during this period, so that these drugs are more useful at later stages after the transplant in which plasma renin activity is greater[33]. Specific beta blockers are considered second-line therapy. Although the ideal blood pressure level in transplant patients has not been established, the suggested levels are < 130/80; for which up to 30% of patients would require at least two drugs[35,36].

***New-onset diabetes***

In cirrhotic patients the prevalence of glucose intolerance is 60-80% and that of diabetes is 10-15%. The incidence of new-onset diabetes after liver transplant (NODALT) ranges from 14%-44%, similar to that seen after other solid-organ transplants (kidney, lung, heart)[37-39]. Pre-transplant diabetes and the BMI have been found in one study to be factors predicting the development of NODALT[9]. NODALT is associated with a high risk of developing CVD and post-transplant mortality[38,40].

The predominant role played by the liver in the regulation of carbohydrate, protein, lipid and drug metabolism makes it the main organ responsible for the maintenance of glucose homeostasis. This has led some authors[41,42] to suggest that it is the liver graft itself that causes the metabolic disorders that occur after the transplant. A high incidence of NODALT has been observed in patients who receive a graft with steatosis, which is associated with insulin resistance[37]. Likewise, grafts from donors after circulatory death have a greater incidence of NODALT, probably in relation to the damage derived from the warm ischemia on the development of insulin resistance[43]. However, in comparison to patients who receive a liver transplant from a deceased donor, patients who receive a liver transplant from a living donor (LDLT) have a lower incidence of NODALT, probably because LDLT livers have more favourable characteristics regarding such factors as age, BMI, or liver function state[43] .

Certain genotype characteristics of the graft are also considered to be determinant in the metabolic status after liver transplantation[44]. Various gene polymorphisms have been associated with metabolic disorders and a particular response to immunosuppressive drugs. This would explain the inter-individual, and even the intra-individual variability of certain drugs like tacrolimus concerning their pharmacokinetic characteristics or dose individualisation[45-47].

Recurrence of the underlying liver disease can also influence the appearance of NODALT. A strong association has been found between early recurrence of hepatitis C and NODALT[48], probably related with the damage to the beta cells induced by the hepatitis C virus (HCV). The recurrence of steatosis/steatohepatitis, which can reach around 60% in patients who receive their transplants for this reason, has also been strongly associated with the development of the MS, as well as diabetes[49]. The association between insulin resistance and beta-cell dysfunction is well known in cirrhosis caused by such agents as alcohol, HCV, or NASH, which all damage beta cells and alter glucose regulation. This results in over 90% of cirrhotic patients becoming intolerant to glucose during the final stages of the disease, with up to 30% developing diabetes[50,51]. Various studies suggest that liver transplantation can resolve up to 70% of cases of pre-transplant diabetes as a result of improving insulin resistance, with the other cases that fail to resolve possibly being due to the persistence of beta-cell injury[52-54]. Nevertheless, these patients all remain exposed to factors associated with the development of diabetes after transplantation, such as immunosuppression, the presence of HCV, or age.

The use of immunosuppressive drugs after liver transplantation plays a crucial role in NODALT. Steroids cause increased insulin resistance and reduced beta-cell secretion. Likewise, calcineurin inhibitors, mainly tacrolimus, have been considered the inducers of NODALT, principally via reduction of insulin secretion by the beta cells through several pathways[55,56]. The mTORs everolimus and sirolimus have not, however, been found to be more effective than tacrolimus in post-transplant blood glucose control[57]; with one study even finding that mTORs reduce beta-cell mass and increase insulin resistance[58]. This has all led to current immunosuppressive regimens tending to use steroid-free protocols and minimisation of the immunosuppression.

Recent studies have also shown the role of the intestinal microbiota in the regulation of carbohydrate metabolism, as well as its influence on the pathogenesis of glucose metabolism disorders. The intestinal microbiota could be affected by liver transplantation through multiple factors, including immunosuppression. Some authors have found an association between the dysbiosis produced by tacrolimus, insulin levels and the insulin resistance index[44].

***Dyslipidaemia***

Although the prevalence of dyslipidaemia in cirrhotic patients is low, due to the alteration in hepatic synthesis, it can nevertheless reach 70% in liver transplant recipients[59-62]. As with other components of the MS, immunosuppression also plays a fundamental role in dyslipidaemia. Steroids produce hypercholesterolaemia and hypertriglyceridaemia due to stimulation of the activity of acetyl-CoA carboxylase and fatty acid synthesis[63,64]. Calcineurin inhibitors can also induce dyslipidaemia, more often cyclosporine than tacrolimus[65-67]. Cyclosporine produces a reduction in biliary cholesterol excretion and blocks the LDL-cholesterol receptors, with the resulting increase in blood levels[36]. mTOR inhibitors induce hypertriglyceridaemia by increasing the activity of adipose tissue lipase and reducing lipoprotein lipase, especially if combined with cyclosporine[68,69].

The treatment of dyslipidaemia should be oriented towards dietary measures, steroid withdrawal and minimisation of immunosuppression. The treatment of post-transplant hypercholesterolaemia generally necessitates the use of drugs since dietary measures alone are not usually effective. Statins are the drugs of choice for the treatment of hypercholesterolaemia. Pravastatin is most recommended because it is not metabolised by the P450 cytochrome and does not interact with the immunosuppression, unlike other statins like simvastatin, fluvastatin, atorvastatin or lovastatin, though these are widely used in transplant recipients with no great problems. Special care is required with the use of ion exchange resins given their effect on the enterohepatic circulation and their repercussion on the absorption of calcineurin inhibitors, particularly cyclosporine. Hypertriglyceridaemia with normal cholesterol concentrations is also usual in liver transplant recipients. It responds best to dietary treatment, particularly the use of omega 3 fatty acids. Drug therapy with fibrates (gemfibrozil) is reserved for severe cases, and is generally well tolerated[33,36,70].

**PREDICTORS OF POST-LIVER TRANSPLANT METABOLIC SYNDROME**

The prevalence of the MS after liver transplantation is around 50%, depending on the criteria used[9]. The factors most consistently related with the risk of developing post-liver transplant MS are a high recipient age at the time of transplant, the presence of diabetes mellitus before transplantation, an increase in BMI after transplantation, smoking and the indication for the transplant (hepatitis C, alcohol or cryptogenic cirrhosis)[9,10,13,71,72]. Some studies have found the use of cyclosporine as an immunosuppressive agent to be a risk factor. In addition, recent studies provide increasing evidence for certain gene polymorphisms as independent risk factors for the development of the MS[39,45,73].

**REPERCUSSION OF THE METABOLIC SYNDROME AFTER LIVER TRANSPLANTATION**

The MS after a liver transplant can have a significant negative impact on post-transplant morbidity and mortality due to its involvement in the development of different clinical aspects directly related with post-transplant survival.

***Cardiovascular risk***

All the components of the MS are considered cardiovascular risk factors. The higher prevalence of the MS in liver transplant recipients is associated with a higher incidence of cardiovascular events than in the general population[74], though the risk is lower than in recipients of a kidney or heart transplant. This is because patients with chronic liver disease experience haemodynamic and metabolic changes resulting from peripheral vasodilation, as well as having low blood pressure and cholesterol levels, which all make these patients less liable to develop cardiovascular events, unlike the situation in kidney or heart transplant recipients. In addition, liver transplant recipients require lower immunosuppression than patients who receive a kidney or heart transplant[75].

The incidence of cardiovascular events after liver transplantation is around 10% at 3 years[30]. Diabetes mellitus, hypertension and having received the transplant due to NAFLD are the risk factors most associated with cardiovascular events[76]. It is important to note that the risk of experiencing a cardiovascular event is 4 times greater in liver-transplant recipients who have the MS than those who do not have it[75]. Around 20% of non-hepatic causes of death in liver transplant patients are due to CVD, which are one of the main causes of death unrelated with the graft[14,77]. Factors predicting cardiovascular events are an older recipient age (OR = 1.2), male gender (OR = 2), NODALT (OR = 2), post-transplant hypertension (OR = 1.8) and the use of mycophenolate mofetil (OR = 2)[30] .

In general, prevention measures and treatment aims in CVD based on studies in the general population are also applicable to liver transplant patients, as no specific studies have yet been undertaken of the impact of these measures in transplant recipients. These recommendations are outlined in Table 2[78].

***Kidney failure***

The presence of the MS in both the general population and in liver transplant recipients is associated with a higher incidence of kidney failure[78]. The reduction in glomerular filtration and the microalbuminuria associated with hypertension or diabetes and the resulting structural damage in the kidney can be increased by the effect of immunosuppressive drugs, which in turn leads to the higher incidence of chronic kidney disease in transplant patients with the MS[79].

***Recurrence of hepatitis C***

There is a bidirectional relationship between hepatitis C and insulin resistance and diabetes, these latter two being recognised as risk factors for the progression of the fibrosis in patients with hepatitis C, whether or not they have received a transplant[80,81]. Additionally, the recurrence of hepatitis C is also recognised as a risk factor for the development of NODALT[60,82] , which in turn is related with greater progression of the fibrosis.

Hepatitis C also affects lipid metabolism, producing a reduction in serum lipid concentrations. Though this could potentially be beneficial, reducing the cardiovascular risk, it has also been related with alterations in the intracellular lipid balance, which could increase the hepatic steatosis [83].

The use of current direct-action antiviral agents against HCV and their high rate of efficacy has led to the recurrence of HCV becoming much less prevalent, with the resulting lower rate of possible effects on metabolic factors.

***NAFLD and NASH***

NAFLD and NASH can be considered hepatic events of the MS[23]. Around 20% of patients with NASH can eventually develop cirrhosis and require liver transplantation. Over 60% of the patients who receive a transplant due to NASH experience a recurrence during the first year, with the main risk factor being the presence of the MS[84]. One study found that around 20% of liver transplant patients who did not previously have fatty liver developed NAFLD afterwards and around 10% developed NASH post-transplant[85]. On the other hand, various studies have identified a 10% increase in the BMI as the main risk factor for the development of NAFLD[49,74,86]. Nonetheless, the true impact of the presence of NAFLD and NASH after transplantation still remains unclear.

**CONCLUSION**

The high prevalence of the MS after a liver transplant and its relation with the development of cardiovascular events, as well as its involvement in other clinical aspects after the transplant that can seriously influence morbidity and mortality, necessitates the early identification of these factors to achieve adequate management of the risks, thereby minimising their impact on patient survival. Other aspects in post-transplant MS, such as the role of gene polymorphisms or the gut microbiota require much greater study.

**REFERENCES**

1 **Pagadala M**, Dasarathy S, Eghtesad B, McCullough AJ. Posttransplant metabolic syndrome: an epidemic waiting to happen. *Liver Transpl* 2009; **15**: 1662-1670 [PMID: 19938136 DOI: 10.1002/lt.21952]

2 **Belle SH**, Porayko MK, Hoofnagle JH, Lake JR, Zetterman RK. Changes in quality of life after liver transplantation among adults. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Liver Transplantation Database (LTD). *Liver Transpl Surg* 1997; **3**: 93-104 [PMID: 9346722 DOI: 10.1002/lt.500030201]

3 **Germani G**, Theocharidou E, Adam R, Karam V, Wendon J, O'Grady J, Burra P, Senzolo M, Mirza D, Castaing D, Klempnauer J, Pollard S, Paul A, Belghiti J, Tsochatzis E, Burroughs AK. Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. *J Hepatol* 2012; **57**: 288-296 [PMID: 22521347 DOI: 10.1016/j.jhep.2012.03.017]

4 **Watt KD**, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. *Am J Transplant* 2010; **10**: 1420-1427 [PMID: 20486907 DOI: 10.1111/j.1600-6143.2010.03126.x]

5 **Johnston SD**, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. *Transplantation* 2002; **73**: 901-906 [PMID: 11923689 DOI: 10.1097/00007890-200203270-00012]

6 **Vogt DP**, Henderson JM, Carey WD, Barnes D. The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. *Surgery* 2002; **132**: 775-80; discussion 780 [PMID: 12407365 DOI: 10.1067/msy.2002.128343]

7 [**National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)**](http://www.ncbi.nlm.nih.gov/pubmed/?term=National%20Cholesterol%20Education%20Program%20(NCEP)%20Expert%20Panel%20on%20Detection%2C%20Evaluation%2C%20and%20Treatment%20of%20High%20Blood%20Cholesterol%20in%20Adults%20(Adult%20Treatment%20Panel%20III)%5BCorporate%20Author%5D)**.** Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002; **106**: 3143-3421 [PMID: 12485966]

8 **Grundy SM**, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005; **112**: 2735-2752 [PMID: 16157765 DOI: 10.1161/CIRCULATIONAHA.105.169404]

9 **Bianchi G**, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. *Liver Transpl* 2008; **14**: 1648-1654 [PMID: 18975273 DOI: 10.1002/lt.21588]

10 **Laryea M**, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, Nashan B, Peltekian KM. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. *Liver Transpl* 2007; **13**: 1109-1114 [PMID: 17663411 DOI: 10.1002/lt.21126]

11 **Ford ES**, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002; **287**: 356-359 [PMID: 11790215 DOI: 10.1001/jama.287.3.356]

12 **Francioso S**, Angelico F, Baiocchi I, Tisone G, Lenci I, Carbone M, Angelico M. High prevalence of metabolic syndrome and long-term survival after liver transplantation. *J Hepato*l 2008; **48**: S82-S82 [doi: 0.1016/S0168-8278(08)60198-1]

13 **Anastácio LR**, Ferreira LG, Ribeiro Hde S, Liboredo JC, Lima AS, Correia MI. Metabolic syndrome after liver transplantation: prevalence and predictive factors. *Nutrition* 2011; **27**: 931-937 [PMID: 21621388 DOI: 10.1016/j.nut.2010.12.017]

14 . Abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases, 2008. October 31-November 4, 2008. San Francisco, California, USA. *Hepatology* 2008; **48 Suppl 1**: 309A-1187A [PMID: 18816472]

15 **Gami AS**, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. *J Am Coll Cardiol* 2007; **49**: 403-414 [PMID: 17258085 DOI: 10.1016/j.jacc.2006.09.032]

16 **Charlton MR**, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. *Gastroenterology* 2011; **141**: 1249-1253 [PMID: 21726509 DOI: 10.1053/j.gastro.2011.06.061]

17 **Wong RJ**, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology* 2015; **148**: 547-555 [PMID: 25461851 DOI: 10.1053/j.gastro.2014.11.039]

18 Stepanova M, Henry L, Garg R, Kalwaney S, Saab S, Younossi Z. Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. BMC Gastroenterology 2015; 15: 175 [PMID 26666336 DOI: 10.1186/s12876-015-0407-y]

19 **Bays HE**, González-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, Rodbard HW, Henry RR. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. *Expert Rev Cardiovasc Ther* 2008; **6**: 343-368 [PMID: 18327995 DOI: 10.1586/14779072.6.3.343]

20 **Fox CS**, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D'Agostino RB, O'Donnell CJ. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. *Circulation* 2007; **116**: 39-48 [PMID: 17576866 DOI: 10.1161/CIRCULATIONAHA.106.675355]

21 **Richards J**, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. *Transpl Int* 2005; **18**: 461-466 [PMID: 15773968 DOI: /10.1111/j.1432-2277.2004.00067.x]

22 **Everhart JE**, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. *Liver Transpl Surg* 1998; **4**: 285-296 [PMID: 9649642]

23 **Shaker M**, Tabbaa A, Albeldawi M, Alkhouri N. Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. *World J Gastroenterol* 2014; **20**: 5320-5330 [PMID: 24833862 DOI: 10.3748/wjg.v20.i18.5320]

24 **Nair S**, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. *Hepatology* 2002; **35**: 105-109 [PMID: 11786965 DOI: 10.1053/jhep.2002.33160]

25 **Leonard J**, Heimbach JK, Malinchoc M, Watt K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. *Am J Transplant* 2008; **8**: 667-672 [PMID: 18294163]

26 **LaMattina JC**, Foley DP, Fernandez LA, Pirsch JD, Musat AI, D'Alessandro AM, Mezrich JD. Complications associated with liver transplantation in the obese recipient. *Clin Transplant* 2012; **26**: 910-918 [PMID: 22694047]

27 **Dick AA**, Spitzer AL, Seifert CF, Deckert A, Carithers RL, Reyes JD, Perkins JD. Liver transplantation at the extremes of the body mass index. *Liver Transpl* 2009; **15**: 968-977 [PMID: 19642131 DOI: 10.1002/lt.21785]

28 **Martínez-Saldivar B**, Prieto J, Berenguer M, de la Mata M, Pons JA, Serrano T, Rafael-Valdivia L, Aguilera V, Barrera P, Parrilla P, Lorente S, Rubin A, Fraga E, Rimola A. Control of blood pressure in liver transplant recipients. *Transplantation* 2012; **93**: 1031-1037 [PMID: 22411562 DOI: 10.1097/TP.0b013e31824cd5e6]

29 **Parekh J**, Corley DA, Feng S. Diabetes, hypertension and hyperlipidemia: prevalence over time and impact on long-term survival after liver transplantation. *Am J Transplant* 2012; **12**: 2181-2187 [PMID: 22548965 DOI: 10.1111/j.1600-6143.2012.04077.x]

30 **Albeldawi M**, Aggarwal A, Madhwal S, Cywinski J, Lopez R, Eghtesad B, Zein NN. Cumulative risk of cardiovascular events after orthotopic liver transplantation. *Liver Transpl* 2012; **18**: 370-375 [PMID: 22140067 ]

31 **Canzanello VJ**, Textor SC, Taler SJ, Schwartz LL, Porayko MK, Wiesner RH, Krom RA. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). *Liver Transpl Surg* 1998; **4**: 328-334 [PMID: 9649648 DOI: 10.1002/lt.500040404]

32 **Textor SC**, Schwartz L, Wilson DJ, Wiesner R, Romero JC, Augustine J, Kos P, Hay E, Gores G, Dickson ER. Systemic and renal effects of nifedipine in cyclosporine-associated hypertension. *Hypertension* 1994; **23**: I220-I224 [PMID: 8282363 DOI: 10.1161/01.HYP.23.1\_Suppl.I220]

33 **De Luca L**, Westbrook R, Tsochatzis EA. Metabolic and cardiovascular complications in the liver transplant recipient. *Ann Gastroenterol* 2015; **28**: 183-192 [PMID: 25830307]

34 **Gonwa T**, Mendez R, Yang HC, Weinstein S, Jensik S, Steinberg S. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. *Transplantation* 2003; **75**: 1213-1220 [PMID: 12717205 DOI: 10.1097/01.TP.0000062837.99400.60]

35 **Neal DA**, Tom BD, Luan J, Wareham NJ, Gimson AE, Delriviere LD, Byrne CD, Alexander GJ. Is there disparity between risk and incidence of cardiovascular disease after liver transplant? *Transplantation* 2004; **77**: 93-99 [PMID: 14724441 DOI: 10.1097/01.TP.0000100685.70064.90]

36 **Watt KD**, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. *J Hepatol* 2010; **53**: 199-206 [PMID: 20451282 DOI: 10.1016/j.jhep.2010.01.040]

37 **Honda M**, Asonuma K, Hayashida S, Suda H, Ohya Y, Lee KJ, Yamamoto H, Takeichi T, Inomata Y. Incidence and risk factors for new-onset diabetes in living-donor liver transplant recipients. *Clin Transplant* 2013; **27**: 426-435 [PMID: 23464510 DOI: 10.1111/ctr.12103]

38 **Lv C**, Zhang Y, Chen X, Huang X, Xue M, Sun Q, Wang T, Liang J, He S, Gao J, Zhou J, Yu M, Fan J, Gao X. New-onset diabetes after liver transplantation and its impact on complications and patient survival. *J Diabetes* 2015; **7**: 881-890 [PMID: 25676209 DOI: 10.1111/1753-0407.12275]

39 **Ling Q**, Xie H, Lu D, Wei X, Gao F, Zhou L, Xu X, Zheng S. Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population. *J Hepatol* 2013; **58**: 271-277 [PMID: 23041303 DOI: 10.1016/j.jhep.2012.09.025]

40 **Wauters RP**, Cosio FG, Suarez Fernandez ML, Kudva Y, Shah P, Torres VE. Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation. *Transplantation* 2012; **94**: 377-382 [PMID: 22820698 DOI: 10.1097/TP.0b013e3182584831]

41 **Stockmann M**, Konrad T, Nolting S, Hünerbein D, Wernecke KD, Döbling H, Steinmüller T, Neuhaus P. Major influence of liver function itself but not of immunosuppression determines glucose tolerance after living-donor liver transplantation. *Liver Transpl* 2006; **12**: 535-543 [PMID: 16496277 DOI: 10.1002/lt.20633]

42 **Gebhardt S**, Jara M, Malinowski M, Seehofer D, Puhl G, Pratschke J, Stockmann M. Risk factors of metabolic disorders after liver transplantation: an analysis of data from fasted patients. *Transplantation* 2015; **99**: 1243-1249 [PMID: 25539465 DOI: 10.1097/TP.0000000000000499]

43 **Yadav AD**, Chang YH, Aqel BA, Byrne TJ, Chakkera HA, Douglas DD, Mulligan DC, Rakela J, Vargas HE, Carey EJ. New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database. *J Transplant* 2013; **2013**: 269096 [PMID: 24205434]

44 **Ling Q**, Xu X, Wang B, Li L, Zheng S. The Origin of New-Onset Diabetes After Liver Transplantation: Liver, Islets, or Gut? *Transplantation* 2016; **100**: 808-813 [PMID: 26910326 DOI: 10.1097/TP.00000000001111]

45 **Neve B**, Le Bacquer O, Caron S, Huyvaert M, Leloire A, Poulain-Godefroy O, Lecoeur C, Pattou F, Staels B, Froguel P. Alternative human liver transcripts of TCF7L2 bind to the gluconeogenesis regulator HNF4α at the protein level. *Diabetologia* 2014; **57**: 785-796 [PMID: 24463962 DOI: 10.1007/s00125-013-3154-z]

46 **Ling Q**, Xu X, Wang K, Wang C, Xiang P, Zhang X, Zhuang R, Xie H, Zheng S. Donor PPARα Gene Polymorphisms Influence the Susceptibility to Glucose and Lipid Disorders in Liver Transplant Recipients: A Strobe-Compliant Observational Study. *Medicine (Baltimore)* 2015; **94**: e1421 [PMID: 26334901 DOI: 10.1097/MD.0000000000001421]

47 **Yu S**, Wu L, Jin J, Yan S, Jiang G, Xie H, Zheng S. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. *Transplantation* 2006; **81**: 46-51 [PMID: 16421475 DOI: 10.1097/01.tp.0000188118.34633.bf]

48 **Gelley F**, Zadori G, Firneisz G, Wagner L, Fehervári I, Gerlei Z, Fazakas J, Papai S, Lengyel G, Sarvary E, Nemes B. Relationship between hepatitis C virus recurrence and de novo diabetes after liver transplantation: the Hungarian experience. *Transplant Proc* 2011; **43**: 1281-1282 [PMID: 21620111 DOI: 10.1016/j.transproceed.2011.03.065]

49 **Dureja P**, Mellinger J, Agni R, Chang F, Avey G, Lucey M, Said A. NAFLD recurrence in liver transplant recipients. *Transplantation* 2011; **91**: 684-689 [PMID: 21248661 DOI: 10.1097/TP.0b013e31820b6b84]

50 **Grancini V**, Trombetta M, Lunati ME, Zimbalatti D, Boselli ML, Gatti S, Donato MF, Resi V, D'Ambrosio R, Aghemo A, Pugliese G, Bonadonna RC, Orsi E. Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease. *J Hepatol* 2015; **63**: 1484-1490 [PMID: 26297917 DOI: 10.1016/j.jhep.2015.08.011]

51 **Hickman IJ**, Macdonald GA. Impact of diabetes on the severity of liver disease. *Am J Med* 2007; **120**: 829-834 [PMID: 17904449 DOI: 10.1016/j.amjmed.2007.03.025]

52 **Ling Q**, Xu X, Wei Q, Wei X, Wang Z, Zhou L, Zheng S. Impact of preexisting diabetes mellitus on outcome after liver transplantation in patients with hepatitis B virus-related liver disease. *Dig Dis Sci* 2011; **56**: 889-893 [PMID: 20703811 DOI: 10.1007/s10620-010-1358-3]

53 **Perseghin G**, Mazzaferro V, Sereni LP, Regalia E, Benedini S, Bazzigaluppi E, Pulvirenti A, Leão AA, Calori G, Romito R, Baratti D, Luzi L. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. *Hepatology* 2000; **31**: 694-703 [PMID: 10706560 DOI: 10.1002/hep.510310320]

54 **Xu X**, Ling Q, He ZL, Gao F, Zheng SS. Post-transplant diabetes mellitus in liver transplantation: Hangzhou experience. *Hepatobiliary Pancreat Dis Int* 2008; **7**: 465-470 [PMID: 18842490]

55 **Rostambeigi N**, Lanza IR, Dzeja PP, Deeds MC, Irving BA, Reddi HV, Madde P, Zhang S, Asmann YW, Anderson JM, Schimke JM, Nair KS, Eberhardt NL, Kudva YC. Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. *Transplantation* 2011; **91**: 615-623 [PMID: 21200364 DOI: 10.1097/TP.0b013e3182094a33]

56 **Chakkera HA**, Mandarino LJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. *Transplantation* 2013; **95**: 647-652 [PMID: 23076551 DOI: 10.1097/TP.0b013e31826e592e]

57 **Klintmalm GB**, Nashan B. The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. *J Transplant* 2014; **2014**: 845438 [PMID: 24719752]

58 **Fraenkel M**, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, Berthault MF, Magnan C, Cerasi E, Kaiser N, Leibowitz G. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. *Diabetes* 2008; **57**: 945-957 [PMID: 18174523 DOI: 10.2337/db07-0922]

59 **Ruiz-Rebollo ML**, Sánchez-Antolín G, García-Pajares F, Fernández-Orcajo P, González-Sagrado M, Cítores-Pascual MA, Velicia-Llames R, Caro-Patón A. Risk of development of the metabolic syndrome after orthotopic liver transplantation. *Transplant Proc* 2010; **42**: 663-665 [PMID: 20304218 DOI: 10.1016/j.transproceed.2010.02.018]

60 **Pérez MJ**, García DM, Taybi BJ, Daga JA, Rey JM, Grande RG, Lombardo JD, López JM. Cardiovascular risk factors after liver transplantation: analysis of related factors. *Transplant Proc* 2011; **43**: 739-741 [PMID: 21486587 DOI: 10.1016/j.transproceed.2011.03.004]

61 **Laish I**, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. *Liver Transpl* 2011; **17**: 15-22 [PMID: 21254340 DOI: 10.1002/lt.22198]

62 **Kallwitz ER**. Metabolic syndrome after liver transplantation: preventable illness or common consequence? *World J Gastroenterol* 2012; **18**: 3627-3634 [PMID: 22851856 DOI: 10.3748/wjg.v18.i28.3627]

63 **Stegall MD**, Everson GT, Schroter G, Karrer F, Bilir B, Sternberg T, Shrestha R, Wachs M, Kam I. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. *Hepatology* 1997; **25**: 173-177 [PMID: 8985286 DOI: 10.1002/hep.510250132]

64 **Boillot O**, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. *Liver Transpl* 2005; **11**: 61-67 [PMID: 15690537 DOI: 10.1002/lt.20307]

65 **Rabkin JM**, Corless CL, Rosen HR, Olyaei AJ. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. *Am J Surg* 2002; **183**: 595-599 [PMID: 12034401 DOI: 10.1016/S0002-9610(02)00826-7]

66 **Manzarbeitia C**, Reich DJ, Rothstein KD, Braitman LE, Levin S, Munoz SJ. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. *Liver Transpl* 2001; **7**: 93-99 [PMID: 11172391 DOI: 10.1053/jlts.2001.21289]

67 **Roy A**, Kneteman N, Lilly L, Marotta P, Peltekian K, Scudamore C, Tchervenkov J. Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant. *Transplantation* 2006; **82**: 494-500 [PMID: 16926593 DOI: 10.1097/01.tp.0000231711.82193.41]

68 **Trotter JF**, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson G. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. *Liver Transpl* 2001; **7**: 401-408 [PMID: 11349259 DOI: 10.1053/jlts.2001.23916]

69 **Morrisett JD**, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. *Transplant Proc* 2003; **35**: 143S-150S [PMID: 12742487 DOI: 10.1016/S0041-1345(03)00233-1]

70 **Zheng J**, Wang WL. Risk factors of metabolic syndrome after liver transplantation. *Hepatobiliary Pancreat Dis Int* 2015; **14**: 582-587 [PMID: 26663005 DOI: 10.1016/S1499-3872(15)60037-6]

71 **Contos MJ**, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. *Liver Transpl* 2001; **7**: 363-373 [PMID: 11303298 DOI: 10.1053/jlts.2001.23011]

72 **Bigam DL**, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, Greig PD, Lilly LB, Heathcote JE, Levy GA, Cattral MS. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. *Hepatology* 2000; **32**: 87-90 [PMID: 10869293 DOI: 10.1053/jhep.2000.8270]

73 **Boj SF**, van Es JH, Huch M, Li VS, José A, Hatzis P, Mokry M, Haegebarth A, van den Born M, Chambon P, Voshol P, Dor Y, Cuppen E, Fillat C, Clevers H. Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. *Cell* 2012; **151**: 1595-1607 [PMID: 23260145 DOI: 10.1016/j.cell.2012.10.053]

74 **Madhwal S**, Atreja A, Albeldawi M, Lopez R, Post A, Costa MA. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. *Liver Transpl* 2012; **18**: 1140-1146 [PMID: 22821899 DOI: 10.1002/lt.23508]

75 **Martin P**, DiMartini A, Feng S, Brown R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. *Hepatology* 2014; **59**: 1144-1165 [PMID: 24716201 DOI: 10.1002/hep.26972]

76 **Vanwagner LB**, Bhave M, Te HS, Feinglass J, Alvarez L, Rinella ME. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. *Hepatology* 2012; **56**: 1741-1750 [PMID: 22611040 DOI: 10.1002/hep.25855]

77 **Pruthi J**, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, Steinbrecher UP, Fong TL. Analysis of causes of death in liver transplant recipients who survived more than 3 years. *Liver Transpl* 2001; **7**: 811-815 [PMID: 11552217 DOI: 10.1053/jlts.2001.27084]

78 **González Grande R**, Jiménez-Pérez M, Sáez Gómez AB, Rodrigo López JM. Metabolic syndrome after liver transplantation. In: Hesham Abdeldayem, Naglaa Allam. Liver Transplantation - Technical Issues and Complications. Croatia: InTech, 2012: 349-360

79 **Morales JM**, Domínguez-Gil B, Gutiérrez MJ. [Impact of immunossuppression in the cardiovascular risk profile after renal transplantation I]. *Nefrologia* 2006; **26**: 181-194 [PMID: 16808256]

80 **Veldt BJ**, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, Heimbach JK, Janssen HL, Charlton MR. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. *Am J Transplant* 2009; **9**: 1406-1413 [PMID: 19459812 DOI: 10.1111/j.1600-6143.2009.02642.x]

81 **Hanouneh IA**, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L, Lopez R, Zein NN. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. *Liver Transpl* 2008; **14**: 1287-1293 [PMID: 18756451 DOI: 10.1002/lt.21524]

82 **Chen T**, Jia H, Li J, Chen X, Zhou H, Tian H. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. *Transpl Int* 2009; **22**: 408-415 [PMID: 19207185 DOI: 10.1111/j.1432-2277.2008.00804.x]

83 **Syed GH**, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. *Trends Endocrinol Metab* 2010; **21**: 33-40 [PMID: 19854061 DOI: 10.1016/j.tem.2009.07.005]

84 **El Atrache MM**, Abouljoud MS, Divine G, Yoshida A, Kim DY, Kazimi MM, Moonka D, Huang MA, Brown K. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome. *Clin Transplant* 2012; **26**: E505-E512 [PMID: 23061759 DOI: 10.1111/ctr.12014]

85 **Seo S**, Maganti K, Khehra M, Ramsamooj R, Tsodikov A, Bowlus C, McVicar J, Zern M, Torok N. De novo nonalcoholic fatty liver disease after liver transplantation. *Liver Transpl* 2007; **13**: 844-847 [PMID: 17029282 DOI: 10.1002/lt.20932]

86 **Lim LG**, Cheng CL, Wee A, Lim SG, Lee YM, Sutedja DS, Da Costa M, Prabhakaran K, Wai CT. Prevalence and clinical associations of posttransplant fatty liver disease. *Liver Int* 2007; **27**: 76-80 [PMID: 17241384 DOI: 10.1111/j.1478-3231.2006.01396.x]

**P-Reviewer:** Bramhall S, Hoyer DP, Kallwitz ER **S-Editor:** Gong ZM

**L-Editor:** **E-Editor:**

**Table 1** **Definition of the metabolic syndrome by the National Cholesterol Education Program, Adult Treatment Panel III adapted by the National Heart, Lung and Blood Institute/American Heart Association, and the International Diabetes Federation**

|  |  |
| --- | --- |
| **American Heart Association** | **International Diabetes Federation** |
| At least 3 of the following criteria:  Waist circumference > 88 cm for women and > 102 cm for men  Fasting glucose > 100 mg/dl  Systolic blood pressure > 130 mmHg and/or diastolic blood pressure > 85 mmHg  HDL < 50 mg/dl for women and < 40 mg/dl for men  Triglycerides > 150 mg/dl | Abdominal obesity according to gender and ethnicity specific values (*i.e.* waist circumference > 80 cm for women and > 90 cm for men if they are American or European) and at least 2 the following criteria:  Fasting glucose > 100 mg/dl  Systolic blood pressure > 130 mmHg and/or diastolic blood pressure > 85 mmHg  HDL < 50 mg/dl for women and < 40 mg/dl for men  Triglycerides >150 mg/dl |

HDL: high density lipoprotein.

**Table 2 Recommendations and treatment aims in patients with the metabolic syndrome**

|  |
| --- |
| Maintain a healthy lifestyle |
| Stop smoking |
| Perform regular physical exercise |
| Weight control |
| Blood pressure  < 140/90 mmHg (if there are no other associated risk factors)  < 130/80 mmHg (if diabetes, kidney failure or established cardiovascular disease) |
| Fasting blood glucose levels: 80-130 mg/dl  Post-prandial levels:140-180 mg/dl  Glycated haemoglobin < 6.5%-7% |
| LDL cholesterol level  < 130 mg/dl (if no cardiovascular risk)  < 115 mg/dl (if moderate cardiovascular risk)  < 110 mg/dl (if high cardiovascular risk) |

HDL: high density lipoprotein.